January 11, 2019
Wakamoto said on January 10 that it has launched a PIII study in Japan for WP-1303 for the treatment of glaucoma and ocular hypertension. Originated by Nagoya-based drug discovery startup D. Western Therapeutics Institute, WP-1303 is an inhibitor of various...read more